C07K 2317/14
Specific host cells or culture conditions
Official title: Specific host cells or culture conditions, e.g. components, pH or temperature
C07K2317/14 (Specific host cells or culture conditions) appears on 1,868 US grants and 3,366 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,868
- Published applications
- 3,366
- Assignees
- 1,058
- Inventors
- 5,497
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 3 | 5 |
| 2004 | 1 | 8 |
| 2005 | 1 | 15 |
| 2006 | 4 | 20 |
| 2007 | 1 | 18 |
| 2008 | 7 | 21 |
| 2009 | 16 | 50 |
| 2010 | 23 | 42 |
| 2011 | 27 | 74 |
| 2012 | 39 | 111 |
| 2013 | 51 | 135 |
| 2014 | 84 | 189 |
| 2015 | 132 | 260 |
| 2016 | 175 | 350 |
| 2017 | 176 | 282 |
| 2018 | 170 | 216 |
| 2019 | 152 | 236 |
| 2020 | 186 | 182 |
| 2021 | 130 | 206 |
| 2022 | 118 | 183 |
| 2023 | 96 | 160 |
| 2024 | 113 | 234 |
| 2025 | 93 | 194 |
| 2026 | 68 | 174 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for modulating FLRT3 mediated signal transduction6 Oct 2026US 12,753,229 B2Nextcure, Inc.
- Manufacturing methods for producing anti-IL12/IL23 antibody compositions29 Sep 2026US 12,747,289 B2Janssen Biotech, Inc.
- Human IL-33 antibodies, preparation method and conjugates thereof and method of use thereof for treatment22 Sep 2026US 12,742,005 B2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Binding molecules for the treatment of cancer22 Sep 2026US 12,742,022 B2Boehringer Ingelheim International GmbH
- Tau binding compounds8 Sep 2026US 12,729,234 B2Voyager Therapeutics, Inc.
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Selective reduction of cysteine residues in il-17 antibodies8 Oct 2026US 2026/0308247 A1Novartis AG
- Selective reduction of cysteine residues in il-17 antibodies8 Oct 2026US 2026/0308248 A1Novartis AG
- Anxiolytic therapy8 Oct 2026US 2026/0308253 A1
- Methods and means for the production of ig-like molecules8 Oct 2026US 2026/0308655 A1Merus N.V.
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity604US 6,602,684 B1GlycArt Biotechnology AG · 2003
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Polypeptide variants with altered effector function373US 7,332,581 B2Genentech, Inc. · 2008